PE13999A1 - Composiciones farmaceuticas estabilizadas a base de quinupristina y de dalfopristina y su preparacion - Google Patents
Composiciones farmaceuticas estabilizadas a base de quinupristina y de dalfopristina y su preparacionInfo
- Publication number
- PE13999A1 PE13999A1 PE1997001017A PE00101797A PE13999A1 PE 13999 A1 PE13999 A1 PE 13999A1 PE 1997001017 A PE1997001017 A PE 1997001017A PE 00101797 A PE00101797 A PE 00101797A PE 13999 A1 PE13999 A1 PE 13999A1
- Authority
- PE
- Peru
- Prior art keywords
- dalphopristine
- quinupristine
- preparation
- composition
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
CARACTERIZADAS PORQUE COMPRENDEN: DE 5 mg/ml A 250 mg/ml DE LA ASOCIACION QUINUPRISTINA/DALFOPRISTINA; UNA CANTIDAD AL MENOS ESTEQUIOMETRICA DE ACIDO METANOSULFONICO o HCl; Y OPCIONALMENTE PUEDEN COMPRENDER UN AGENTE ISOTONIZANTE Y/O OTROS ADYUVANTES; EN DONDE EL pH DE LA COMPOSICION ESTA EN EL RANGO DE 3,5 A 5. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION DE DICHA COMPOSICION, QUE COMPRENDE: DISOLVER SIMULTANEA O SUCESIVAMENTE LA QUINUPRISTINA Y A CONTINUACION LA DALFOPRISTINA EN AGUA ACIDIFICADA CON ACIDO METANOSULFONICO o CON HCl, Y A CONTINUACION AJUSTAR EL pH DE 3,5 A 5; FINALMENTE, LA SOLUCION OBTENIDA SE LIOFILIZA Y/O SE CONGELA. LA COMPOSICION ESTABILIZADA, LIOFILIZADA O CONGELADA PRESENTA COMO VENTAJA ESTABILIDAD FISICOQUIMICA OPTIMA QUE PERMITE SU ALMACENAMIENTO Y POR LO TANTO, COMERCIALIZACION, SIENDO UTIL COMO ANTIBACTERIANO PRINCIPALMENTE SOBRE LOS GERMENES RESISTENTES A LA VANCOMICINA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9614062A FR2755857B1 (fr) | 1996-11-19 | 1996-11-19 | Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE13999A1 true PE13999A1 (es) | 1999-05-05 |
Family
ID=9497744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1997001017A PE13999A1 (es) | 1996-11-19 | 1997-11-13 | Composiciones farmaceuticas estabilizadas a base de quinupristina y de dalfopristina y su preparacion |
Country Status (45)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2772272B1 (fr) * | 1997-12-16 | 2000-01-14 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation |
| HU230656B1 (hu) | 1998-09-25 | 2017-06-28 | Cubist Pharmaceuticals Llc | Daptomicin alkalmazása |
| AU776782C (en) * | 1999-03-03 | 2005-04-07 | Eli Lilly And Company | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
| TWI233805B (en) * | 1999-07-01 | 2005-06-11 | Fujisawa Pharmaceutical Co | Stabilized pharmaceutical composition in lyophilized form as antifungal agent |
| US6119269A (en) * | 1999-09-23 | 2000-09-19 | Imler; Jack | Fishing vest with removable storage container system |
| US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| FR2812549B1 (fr) * | 2000-08-03 | 2003-03-21 | Aventis Pharma Sa | Associations dalfopristine/quinupristine avec le cefpirome |
| US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2549065B1 (fr) * | 1983-07-13 | 1985-10-25 | Rhone Poulenc Sante | Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2576022B1 (fr) * | 1985-01-11 | 1987-09-11 | Rhone Poulenc Sante | Nouveaux derives de la pristinamycine ii b, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2599036B1 (fr) * | 1986-05-22 | 1988-09-09 | Rhone Poulenc Sante | Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent |
-
1996
- 1996-11-19 FR FR9614062A patent/FR2755857B1/fr not_active Expired - Fee Related
-
1997
- 1997-11-13 IN IN3274DE1997 patent/IN187038B/en unknown
- 1997-11-13 PE PE1997001017A patent/PE13999A1/es not_active Application Discontinuation
- 1997-11-14 ES ES97945926T patent/ES2179375T3/es not_active Expired - Lifetime
- 1997-11-14 DE DE69715247T patent/DE69715247T2/de not_active Expired - Lifetime
- 1997-11-14 AU AU51256/98A patent/AU740291B2/en not_active Ceased
- 1997-11-14 EA EA199900479A patent/EA002025B1/ru unknown
- 1997-11-14 TR TR1999/01096T patent/TR199901096T2/xx unknown
- 1997-11-14 RS YUP-224/99A patent/RS49608B/sr unknown
- 1997-11-14 JP JP52326598A patent/JP4278115B2/ja not_active Expired - Lifetime
- 1997-11-14 IL IL12960797A patent/IL129607A0/xx not_active IP Right Cessation
- 1997-11-14 PL PL97333850A patent/PL190164B1/pl not_active IP Right Cessation
- 1997-11-14 EP EP97945926A patent/EP0949923B1/fr not_active Expired - Lifetime
- 1997-11-14 NZ NZ334949A patent/NZ334949A/xx unknown
- 1997-11-14 CN CNB97198901XA patent/CN1146417C/zh not_active Expired - Fee Related
- 1997-11-14 SK SK660-99A patent/SK284311B6/sk not_active IP Right Cessation
- 1997-11-14 MY MYPI97005468A patent/MY123805A/en unknown
- 1997-11-14 WO PCT/FR1997/002047 patent/WO1998022107A1/fr active IP Right Grant
- 1997-11-14 BR BR9713087-7A patent/BR9713087A/pt not_active Application Discontinuation
- 1997-11-14 KR KR10-1999-7004364A patent/KR100530836B1/ko not_active IP Right Cessation
- 1997-11-14 EE EEP199900127A patent/EE03668B1/xx not_active IP Right Cessation
- 1997-11-14 CZ CZ0174899A patent/CZ299913B6/cs not_active IP Right Cessation
- 1997-11-14 CA CA002271095A patent/CA2271095C/fr not_active Expired - Fee Related
- 1997-11-14 UY UY24780A patent/UY24780A1/es not_active IP Right Cessation
- 1997-11-14 DK DK97945926T patent/DK0949923T3/da active
- 1997-11-14 MA MA24866A patent/MA26448A1/fr unknown
- 1997-11-14 HU HU9904327A patent/HUP9904327A3/hu unknown
- 1997-11-14 AT AT97945926T patent/ATE223217T1/de not_active IP Right Cessation
- 1997-11-14 AP APAP/P/1999/001530A patent/AP998A/en active
- 1997-11-14 UA UA99052713A patent/UA59376C2/uk unknown
- 1997-11-14 PT PT97945926T patent/PT949923E/pt unknown
- 1997-11-15 JO JO19971992A patent/JO1992B1/en active
- 1997-11-17 HR HR970615A patent/HRP970615B1/xx not_active IP Right Cessation
- 1997-11-18 TN TNTNSN97184A patent/TNSN97184A1/fr unknown
- 1997-11-18 DZ DZ970199A patent/DZ2349A1/xx active
- 1997-11-19 ZA ZA9710435A patent/ZA9710435B/xx unknown
- 1997-11-19 TW TW086117271A patent/TW474816B/zh not_active IP Right Cessation
- 1997-11-19 CO CO97067661A patent/CO4910113A1/es unknown
- 1997-11-19 AR ARP970105410A patent/AR008695A1/es unknown
- 1997-11-26 SA SA97180645A patent/SA97180645B1/ar unknown
-
1999
- 1999-04-26 IL IL129607A patent/IL129607A/en unknown
- 1999-05-19 BG BG103412A patent/BG63621B1/bg unknown
- 1999-05-19 NO NO992399A patent/NO992399D0/no not_active Application Discontinuation
- 1999-05-19 US US09/314,070 patent/US5994338A/en not_active Expired - Lifetime
- 1999-05-19 OA OA9900100A patent/OA11047A/fr unknown
-
2000
- 2000-03-23 HK HK00101793A patent/HK1022832A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2346662A1 (en) | Compositions containing diphosphonic acids | |
| IE893564L (en) | Novel 3-piperidinyl-1,2-benzisoxazoles | |
| ES2050070B1 (es) | Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica. | |
| ES2160693T3 (es) | Formulacion estable de 10-hidroxi-7-etil-camptotecina en la forma lactona. | |
| YU23599A (sh) | Stabilizovani antihistaminski sirup | |
| DE60023465D1 (de) | Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser | |
| BE2011C028I2 (en) | Macrocyclic analogs and methods of their use and preparation | |
| EE9800173A (et) | Gonadotropiini riliisinghormooni antagonistid | |
| PT1073470E (pt) | Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos | |
| ATE218580T1 (de) | Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen | |
| PE13999A1 (es) | Composiciones farmaceuticas estabilizadas a base de quinupristina y de dalfopristina y su preparacion | |
| GR3034366T3 (en) | Cyclic antimicrobial peptides and preparation thereof. | |
| AU7117498A (en) | Gnrh antagonists | |
| PE38097A1 (es) | NUEVA FORMA CRISTALINA DEL ACIDO 7-([1a, 5a, 6a]-6-AMINO-3-AZABICICLO[3.1.0]HEX-3-IL)-6-FLUOR-1-(2,4-DIFLUOROFENIL)-1,4-DIHIDRO-4-OXO-1,8-NAFTIRIDIN-3-CARBOXILICO ANHIDRO, SAL DEL ACIDO METANOSULFONICO | |
| LT99036A (en) | Local anesthetic for external use | |
| DE69224071D1 (de) | Chinolan-antibiotika und polystyrolsulfonat enthaltende zusammensetzungen | |
| PT866791E (pt) | Diaminopirimidinas formulacoes farmaceuticas que as contem e sua utilizacao antibacteriana | |
| BR9913699A (pt) | Composição inseticida | |
| GR3019274T3 (en) | Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazine-4-ones, their preparation and their therapeutical use | |
| EP1285660A4 (en) | ZINC SUPPLEMENTARY COMPOSITIONS FOR ORAL ADMINISTRATION | |
| IT1196041B (it) | Emichetali di (8s)-8-fluoroeritromicine,il procedimento per la loro preparazione e le formulazioni adatte alla somministrazione orale che contengono i prodotti | |
| ATE331502T1 (de) | 4-amino-1-hydroxybutyliden-1,1-biphosphonsäure enthaltende direktkomprimierte tablette | |
| EA199900352A1 (ru) | Композиции жидкого алендроната | |
| EP0842663A4 (en) | OPHTHALMIC PREPARATIONS | |
| BR9812385A (pt) | Formulações parasiticidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |